Nanohale AG (FYB) | WebDisclosure

Basculer en Français

8205	Companies
109490	Keywords
51631	Articles
60290	Press releases

Home
Companies
Nanohale AG

BRIEF

published on 08/06/2024 at 12:45, 2 months 29 days ago

Formycon AG augmente ses perspectives pour l'exercice 2024

Exercice 2024 Formycon AG EBITDA Ajusté Biosimilaires Fonds De Roulement
BRIEF

published on 08/06/2024 at 12:45, 2 months 29 days ago

Formycon AG Increases 2024 Fiscal Year Outlook

Adjusted EBITDA Working Capital Fiscal Year 2024 Formycon AG Biosimilars
PRESS RELEASE

published on 08/06/2024 at 12:40, 2 months 29 days ago

EQS-Adhoc: Formycon AG increases its outlook for the 2024 fiscal year
Formycon AG increases its 2024 fiscal year outlook based on positive Lucentis biosimilar performance, adjusting EBITDA and working capital forecasts

Adjusted EBITDA Working Capital Formycon AG 2024 Fiscal Year Lucentis Biosimilar
BRIEF

published on 07/30/2024 at 06:55, 3 months 6 days ago

Formycon commence l'essai clinique de phase III pour le biosimilaire Keytruda® FYB206

Essais Cliniques Formycon Biosimilaire FYB206 Keytruda
BRIEF

published on 07/30/2024 at 06:55, 3 months 6 days ago

Formycon Begins Phase III Clinical Trial for Keytruda® Biosimilar FYB206

Clinical Trials Biosimilar Formycon FYB206 Keytruda
PRESS RELEASE

published on 07/30/2024 at 06:50, 3 months 6 days ago

Formycon announces start of clinical phase III trial for Keytruda® biosimilar candidate FYB206
Formycon AG initiates Phase III clinical trial for FYB206, a Keytruda biosimilar, in NSCLC patients in Eastern Europe and Southeast Asia. Study aims to compare safety and efficacy with Keytruda

Formycon AG NSCLC Phase III Trial FYB206 Keytruda Biosimilar
BRIEF

published on 07/26/2024 at 12:05, 3 months 9 days ago

Formycon and Fresenius Kabi Receive Positive CHMP Opinion for FYB202 (Ustekinumab)

Biosimilar Formycon Fresenius Kabi FYB202 CHMP Opinion
BRIEF

published on 07/26/2024 at 12:05, 3 months 9 days ago

Formycon et Fresenius Kabi reçoivent un avis positif du CHMP pour FYB202 (Ustekinumab)

Formycon Fresenius Kabi FYB202 Biosimilaire Avis Du CHMP
PRESS RELEASE

published on 07/26/2024 at 12:00, 3 months 9 days ago

Formycon and Fresenius Kabi receive positive CHMP opinion for FYB202 (Ustekinumab), a biosimilar candidate to Stelara®
Formycon and Fresenius Kabi receive positive CHMP opinion for FYB202 biosimilar candidate to Stelara. Approval expected in early Q4 2024. Biosimilars boost healthcare access & reduce costs globally

Biosimilar Formycon Fresenius Kabi FYB202 CHMP Opinion
BRIEF

published on 07/26/2024 at 10:59, 3 months 9 days ago

FYB202 Biosimilar to Stelara Receives Positive CHMP Opinion from EMA

Biosimilar Formycon FYB202 CHMP EMA

Accesswire

Published on 11/05/2024 at 03:30, 4 hours 26 minutes ago

CORRECTION: Savencia Cheese USA Announces Voluntary Recall of Select Soft Ripened Cheeses
Published on 11/05/2024 at 00:00, 7 hours 56 minutes ago

Axcap Ventures Announces Upsizing of Private Placement
Published on 11/04/2024 at 23:00, 8 hours 56 minutes ago

Jericho Energy Ventures Announces Plan to Separate Hydrogen Platform from Traditional Energy Assets to Maximize Shareholder Value
Published on 11/04/2024 at 23:00, 8 hours 56 minutes ago

APEX/IFSA Global EXPO Showcases the Future of Aviation With Nearly 3,000 Industry ‎Professionals in Attendance
Published on 11/04/2024 at 22:45, 9 hours 11 minutes ago

Alphinat Announces a Profit of $160,597 for Fiscal Year Ended August 31, 2023

View all ACCESSWIRE

EQS Group

Published on 11/05/2024 at 07:45, 11 minutes ago

Schaeffler stays on track in year of transition 2024
Published on 11/05/2024 at 07:30, 26 minutes ago

AUSTRIAN POST Q1–3 2024: Successful first three quarters of 2024 with double-digit revenue growth
Published on 11/05/2024 at 07:29, 26 minutes ago

Evotec Announces Sale of API Manufacturing Facility to Monacum Partners
Published on 11/05/2024 at 07:17, 38 minutes ago

La part élevée de véhicules alternatifs se reflète dans le parc automobile
Published on 11/05/2024 at 07:15, 41 minutes ago

Spexis expects SIX to delist shares of Spexis on the SIX exchange imminently.

Les Echos

Published on 11/05/2024 at 07:45, 11 minutes ago

ALTEN signe un accord définitif pour l'achat de Worldgrid à Atos
Published on 11/05/2024 at 07:45, 11 minutes ago

ALTEN signs a binding agreement to purchase Worldgrid from Atos
Published on 11/04/2024 at 18:13, 13 hours 43 minutes ago

Thales : lancement de l’opération 2024 d’actionnariat salarié
Published on 11/04/2024 at 18:13, 13 hours 43 minutes ago

Thales: Launch of the 2024 Employee Share Ownership Plan
Published on 11/04/2024 at 18:11, 13 hours 44 minutes ago

Monthly disclosure of the total number of shares and voting rights - 31/10/2024

View all LES ECHOS COMFI WIRE